PDF herunterladen
CC BY-NC-ND 4.0 · Thromb Haemost 2022; 122(03): 329-335
DOI: 10.1055/a-1715-5960
Position Paper

Management of DOAC in Patients Undergoing Planned Surgery or Invasive Procedure: Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) Position Paper

Alessandro Squizzato 
1   Research Center on Thromboembolic Disorders and Antithrombotic Therapies, ASST Lariana, University of Insubria, Como, Italy
,
Daniela Poli
2   Thrombosis Center, ‘Careggi’ Hospital, Florence, Italy
,
Doris Barcellona 
3   Thrombosis and Haemostasis Unit, University of Cagliari, Cagliari, Italy
,
Antonio Ciampa
4   Haemostasis Center, ‘Moscati’ Hospital, Avellino, Italy
,
Elvira Grandone 
5   Thrombosis and Haemostasis Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
6   Ob/Gyn Department, The First I.M. Sechenov Moscow State Medical University, Moscow, Russia
,
Cesare Manotti
7   Haemostasis Center, Hospital of Parma, Parma, Italy
,
Marco Moia
8   Haemophilia and Thrombosis Center, IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy
,
Vincenzo Toschi
9   Department of Haematology and Blood Transfusion and Thrombosis Center, Santi Paolo e Carlo Hospital, Milan, Italy
,
Alberto Tosetto
10   Hemophilia and Thrombosis Center, Hematology Department, San Bortolo Hospital, Vicenza, Italy
,
Sophie Testa
11   Haemostasis and Thrombosis Center, ASST Cremona, Cremona, Italy
,
Scientific Reviewer Committee
› Institutsangaben Funding None.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Patients on anticoagulant treatment are constantly increasing, with an estimated prevalence in Italy of 2% of the total population. About a quarter of the anticoagulated patients require temporary cessation of direct oral anticoagulants (DOACs) or vitamin K antagonists for a planned intervention within 2 years from anticoagulation inception. Several clinical issues about DOAC interruption remain unanswered: many questions are tentatively addressed daily by thousands of physicians worldwide through an experience-based balancing of thrombotic and bleeding risks. Among possible valuable answers, the Italian Federation of Centers for the diagnosis of thrombotic disorders and the Surveillance of the Antithrombotic therapies (FCSA) proposes some experience-based suggestions and expert opinions. In particular, FCSA provides practical guidance on the following issues: (1) multiparametric assessment of thrombotic and bleeding risks based on patients' individual and surgical risk factor, (2) testing of prothrombin time, activated partial thromboplastin time, and DOAC plasma levels before surgery or invasive procedure, (3) use of heparin, (4) restarting of full-dose DOAC after high risk bleeding surgery, (5) practical nonpharmacological suggestions to manage patients perioperatively. Finally, FCSA suggests creating a multidisciplinary “anticoagulation team” with the aim to define the optimal perioperative management of anticoagulation.

Keywords

direct oral anticoagulant - surgery - FCSA


Publikationsverlauf

Eingereicht: 04. August 2021

Angenommen: 02. Dezember 2021

Accepted Manuscript online:
07. Dezember 2021

Artikel online veröffentlicht:
07. Februar 2022

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Steffel J, Collins R, Antz M. et al; External reviewers. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace 2021; 23 (10) 1612-1676
    CrossrefPubMedGoogle Scholar
  • 2 Spyropoulos AC, Brohi K, Caprini J. et al; SSC Subcommittee on Perioperative and Critical Care Thrombosis and Haemostasis of the International Society on Thrombosis and Haemostasis. Scientific and Standardization Committee Communication: guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic risk. J Thromb Haemost 2019; 17 (11) 1966-1972
    CrossrefPubMedGoogle Scholar
  • 3 Douketis JD, Spyropoulos AC, Kaatz S. et al; BRIDGE Investigators. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015; 373 (09) 823-833
    CrossrefPubMedGoogle Scholar
  • 4 Douketis JD, Spyropoulos AC, Duncan J. et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med 2019; 179 (11) 1469-1478
    CrossrefPubMedGoogle Scholar
  • 5 Tafur AJ, Clark NP, Spyropoulos AC. et al. Predictors of bleeding in the perioperative anticoagulant use for surgery evaluation study. J Am Heart Assoc 2020; 9 (19) e017316
    CrossrefPubMedGoogle Scholar
  • 6 Shaw JR, Li N, Vanassche T. et al. Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. Blood Adv 2020; 4 (15) 3520-3527
    CrossrefPubMedGoogle Scholar
  • 7 Doherty JU, Gluckman TJ, Hucker WJ. et al. 2017 ACC Expert Consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol 2017; 69 (07) 871-898
    CrossrefPubMedGoogle Scholar
  • 8 Hindricks G, Potpara T, Dagres N. et al; ESC Scientific Document Group. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (05) 373-498
    CrossrefPubMedGoogle Scholar
  • 9 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
    CrossrefPubMedGoogle Scholar